Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OMTX705 + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Oncomatryx
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
OMTX705 + pembrolizumab is a **combination therapy** under investigation for the treatment of advanced solid tumors. OMTX705 is a first-in-class antibody-drug conjugate (ADC) targeting fibroblast activation protein (FAP)-positive cancer-associated fibroblasts (CAFs) in the tumor microenvironment. Its dual mechanism involves direct cytotoxic action against FAP-positive CAFs and enhancement of immune cell infiltration within the tumor, aiming to overcome resistance to both chemotherapy and immunotherapy[3]. Pembrolizumab is a monoclonal antibody acting as a programmed cell death protein 1 (PD-1) checkpoint inhibitor, designed to increase anti-tumor immune responses by preventing PD-1 receptor-mediated inhibition of T cell activity[2][4]. The combination is being studied for increased efficacy and safety in advanced or metastatic cancers for which standard therapies are lacking[1][5].
- Other names
- OMTX705 + pembrolizumab
02
Targets
TUBB (Tubulin (alpha and beta subunits))FAP (Fibroblast activation protein alpha)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on OMTX705 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OMTX705 + pembrolizumab.